Zhang Fu-Gui, Tang Xiu-Fa
Fu-Gui Zhang, Department of Oral and Maxillofacial Surgery, the Affiliated Hospital of Stomatology, Chongqing Medical University, Chongqing 400016, China.
World J Stem Cells. 2014 Sep 26;6(4):491-6. doi: 10.4252/wjsc.v6.i4.491.
Mesenchymal stem cells (MSCs), multipotential cells that reside within the bone marrow, can be induced to differentiate into various cells, such as osteoblasts, adipocytes, chondrocytes, vascular endothelial progenitor cells, and other cell types. MSCs are being widely studied as potential cell therapy agents due to their angiogenic properties, which have been well established by in vitro and in vivo researches. Within this context, MSCs therapy appears to hold substantial promise, particularly in the treatment of conditions involving skin grafts, pedicle flaps, as well as free flaps described in literatures. The purpose of this review is to report the new advances and mechanisms underlying MSCs therapy against skin flaps necrosis.
间充质干细胞(MSCs)是存在于骨髓中的多能细胞,可被诱导分化为多种细胞,如成骨细胞、脂肪细胞、软骨细胞、血管内皮祖细胞和其他细胞类型。由于其血管生成特性已在体外和体内研究中得到充分证实,MSCs作为潜在的细胞治疗药物正受到广泛研究。在此背景下,MSCs治疗似乎具有很大的前景,特别是在治疗涉及皮肤移植、带蒂皮瓣以及文献中描述的游离皮瓣的病症方面。本综述的目的是报告MSCs治疗皮瓣坏死的新进展及其潜在机制。